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Background: Estrogens were recently demonstrated to be synthesized in non-small cell lung carcinomas (NSCLCs)
via aromatase activity and aromatase inhibitor (AI) did suppressed estrogen receptor (ER) positive NSCLC growth.
However, other enzymes involved in intratumoral production and metabolism of estrogens, i.e. 17β-hydroxysteroid
dehydrogenases (i.e. 17βHSD1 and 17βHSD2) and others have not been studied. Therefore, in this study, we
examined the clinical/ biological significance of 17β-hydroxysteroid dehydrogenases in NSCLCs.
Methodology: Archival materials obtained from 103 NSCLC patients were immunohistochemically evaluated using
anti-17βHSD1 and anti-17βHSD2 antibodies. The findings of immunohistochemistry were then correlated with
intratumoral estrone (E1) and estradiol (E2) concentration, clinicopathological factors and overall survival of the
patients. We further employed NSCLC cell lines, A549 and LK87 to study the functional significance of 17βHSD1,
in vitro.
Results: A higher 17βHSD1 immunoreactivity tended to be positively associated with aromatase (p=0.057) and
tumor stage (p=0.055) whereas a higher 17βHSD2 immunoreactivity was positively associated with a squamous cell
and adenosquamous cell carcinomas subtypes (p=0.031), tumor stage (p=0.004), T factor of TNM classification
(p=0.010), maximum tumor diameter (p=0.002) and tended to be associated with N factor of TMN classification
(p=0.065). A higher 17βHSD1 immunoreactivity was also significantly associated with lower intratumoral E1
concentration (p=0.040) and a higher intratumoral E2/E1 concentration ratio (p=0.028). On the other hand a higher
17βHSD2 immunoreactivity was significantly associated with higher intratumoral E1 concentration (p=0.035). Results
of multivariate regression analysis demonstrated an increased 17βHSD1 immunoreactivity in tumor cells as an
independent negative prognostic factor (HR= 2.83, p=0.007). E1 treatment in 17βHSD1 positive NSCLC cells, A549
and LK87, resulted in E2 production (p<0.0001) and enhanced cell proliferation, which was abrogated effectively by
17βHSD1 siRNA knockdown (p<0.0001). In addition, aromatase inhibitor treatment resulted in 17βHSD1 up
regulation in both A549 and LK87 cells.
Conclusion: Results of our present study suggest that 17βHSD1 may be considered an important prognostic factor
in NSCLC patients and targeting 17βHSD1 activity may further improve the clinical response in estrogen responsive
NSCLC patients.
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Lung cancer is the leading cause of cancer mortality
worldwide [1]. Tobacco smoking still remains its prime
cause among both men and women [2] but recent stud-
ies have also demonstrated that estrogens may contrib-
ute to the cell proliferation of some non-small cell lung
carcinoma (NSCLC) cells [3]. Estrogens exert their ef-
fects via estrogen receptors (ERs) which are reported to
be expressed very frequently in human NSCLCs of either
gender, especially ERβ [4]. Both genomic and non-
genomic actions of estradiol (E2) via ERβ have been
reported in NSCLC cells; which result in tumor progres-
sion [5]. Therefore, at least some NSCLC are reasonably
considered novel estrogen dependent neoplasms.
Male NSCLC patients with a high free E2 serum levels
had significantly worse clinical outcome compared to
those with lower E2 levels [6]. However, a frequent aro-
matase expression [7] and the ability of local production
of estrogens via aromatase in estrogen dependent lung
carcinoma cells have also been reported [8]. Due to the
frequent expression of aromatase in NSCLC patients
a phase II randomized trial of aromatase inhibitor
(anastrozole) and ER blocker (fulvestrant) as consolida-
tion therapy in postmenopausal women with advanced
NSCLC was scheduled [9]. However, it is important to
note that aromatase is not the only estrogen producing
enzyme and other enzymes involved with intratumoral
production and metabolism of estrogens, i.e. 17β-
hydroxysteroid dehydrogenases (i.e. 17βHSD1 and
17βHSD2), steroid sulphatse (STS), estrone sulfotrans-
ferase (EST) could also be involved in modulation of
intratumoral estrogens levels in NSCLCs. However, there
have been no studies published on possible roles of
17βHSDs, STS and EST in NSCLC patients.
17βHSD1 catalyzes primarily the reduction of estrone
(E1) to E2, whereas 17βHSD2 catalyzes primarily the
oxidation of E2 to E1, and together they modulate the
overall tissue levels of bioactive E2 in peripheral tissues
including breast cancer [10]. An inhibitory potential of
various novel 17βHSD1 inhibitors have been demon-
strated for the treatment of estrogen-dependent diseases
[11-13].
Based upon the reported findings above, we tentatively
hypothesized that 17βHSDs pathway may play important
roles in lung tumor progression via intratumoral estro-
gens production and regulation. Therefore, in this study,
we first evaluated the status of both 17βHSD1 and
17βHSD2 in 103 NSCLC patients using immunohisto-
chemistry (IHC). We then studied the correlation of the
findings with clinicopathological variables, intratumoral
E1 and/or intratumoral E2 tissue concentrations and
overall survival in individual patients. The activity and
regulation of 17βHSD1 was further examined in NSCLC
cell lines i.e. A549 and LK87.Materials and methods
Patients
103 NSCLC cases were retrieved from surgical pathology
files of Department of Pathology, Tohoku University
Hospital who underwent surgery from 1993 to 2003.
Neither anti-EGFR nor anti-hormonal therapy was ad-
ministered to any of the patients examined prior to sur-
gery. Informed consent was obtained from each patient
before surgery. Research protocols for this study were
approved by the Ethics Committee at Tohoku University
School of Medicine (Approval No. 2009–500).
Immunohistochemistry
Serial tissue sections of 3 μm thickness fixed in 10% formal-
dehyde solution and embedded in paraffin were used for
both hematoxylin-eosin staining and immunohistochemis-
try using labeled streptavidin biotin method. The primary
antibodies used in this study are given as Additional file 1
[14]. Positive controls were invasive ductal carcinoma of
the breast for ERα, adenocarcinoma of the prostate for
ERβ, tonsil for Ki67 and human full term placenta for aro-
matase, 17βHSD1 and 17βHSD2. As a negative control,
normal mouse or rabbit IgG was used instead of the pri-
mary antibodies and no specific immunoreactivity was
detected in these sections (data not shown). Immunoreac-
tivity of ERα, ERβ, Ki-67/MIB1 and steroidogenic enzymes
i.e. aromatase, 17βHSD1 and 17βHSD2 was counted
among 1000 cells per case at hot spots and was determined
as “positive” if immunereactivity was detected in more than
10% of cells, as previously described [15-17]. Based on the
relative immunointensity of 17βHSD1 and/or 17βHSD2 in
cytoplasm of the patients, the cases were classified as low
(negative or weakly positive) and high (moderately/strongly
positive), also according to the previous report [18]. The
evaluation of immunohistochemical stains was done inde-
pendently by two of the authors (M.K.V. and T.S.) that
were blinded to the results for each antibody.
Liquid chromatography/electrospray tandem mass
spectrometry
Among 103 NSCLC patients, 48 paired frozen specimen
of lung carcinomas and corresponding non-neoplastic
lung tissues were available for liquid chromatography/
electrospray tandem mass spectrometry for measure-
ment of intratumoral E1 concentrations as previously
reported [17,19]. We previously reported intratumoral
E2 concentrations in these 48 patients [19]. The detailed
methods of analyzing the intratumoral estrogens con-
centrations were also described in the report above.
Cell culture and chemicals
Human NSCLC cell lines i.e. A549 and LK87 were pro-
vided by Institute of Development, Aging and Cancer,
Tohoku University. Both of the cell lines were lung
Verma et al. Journal of Translational Medicine 2013, 11:167 Page 3 of 11
http://www.translational-medicine.com/content/11/1/167adenocarcinomas of male origin i.e. A549 (ATCC data
sheet) and LK87 [20,21]. The cells were cultured in RPMI
1640 (Sigma-Aldrich) with 10% fetal bovine serum
(Nichirei Co. Ltd.). Cells were incubated at 37°C in a hu-
midified atmosphere containing 5% CO2. E1, E2 and testos-
terone were commercially obtained from Sigma-Aldrich.
Quantitative RT-PCR
Total RNA was extracted using TRIzol reagent
(Invitrogen Life Technologies) and cDNA was synthe-
sized using a QuantiTect reverse transcription kit
(Qiagen). Quantitative real-time PCR was carried out
using the LightCycler System and FastStart DNA Master
SYBR Green I (Roche Diagnostics). Ribosomal protein L
13a (RPL13A) was also used as an internal standard. The
primer sequences used in this study are given as
Additional file 2.
ELISA assay
Cells were serum starved for 24 hours in a 24-well plate
and then treated with steroids for 24 hours. Supernatant
media was collected and evaluated for estrogen produc-
tion using Estradiol EIA Kit (Cayman Chemical Com-
pany) according to the manufacturer’s protocol. An
appropriate standard curve was plotted and the concen-
tration of estradiol was determined.
siRNA transfections
One scramble siRNA as a control and two 17βHSD1
specific siRNA were purchased from Sigma-Aldrich. The
sense and antisense sequences of the two 17β-HSD1
siRNA, as described in the previous report [22] are given
as Additional file 3. 200 nM of either 17βHSD1 siRNA 1
or 2 was transfected in NSCLC cell lines, i.e. A549 and
LK87 cells, using G-fectin kit (Genolution Pharmaceuti-
cals, Inc.) according to manufacturer’s protocol. Cells
were harvested after 72 hours of siRNA transfections
and evaluated for 17βHSD1 expression and/or activity.
Cell proliferation assay
Cells were serum starved for 24 hours in a 96-well plate
and then treated with test compounds and/or siRNA
transfections for 72 hours. Then cells were harvested
and evaluated for cell proliferation using WST-8 method
(Cell Counting Kit-8; DOJINDO Laboratories). Optical
densities (OD, 450 nm) were obtained with a microplate
spectrophotometry (Model680, Bio-Rad Laboratories).
Immunoblotting
Cells were serum starved for 24 hours in a 6 well plate
and then treated with test compounds and/or siRNA
transfections for an adequate length of time. 10 micro-
grams of the proteins from the cells were subjected toSDS-PAGE (10% acrylamide gel, SuperSep™Ace: Wako).
The primary antibodies used were anti-17βHSD1
(1:1000; clone 2E5; Abnova) and anti-β-actin (1:1000;
clone AC-15, Sigma–Aldrich). These antibody–protein
complexes on the blots were detected using ECL-plus
Western blotting detection reagents (GE Healthcare)
using LAS-1000 cooled CCD-camera chemiluminescent
image analyzer (Fuji Photo Film Co., Ltd.).
Statistical analysis
For the statistical analysis in this study, we used
STATVIEW version 5.0 (J software, SAS Institute Inc.,
USA). Statistical analyses used Fisher’s PLSD test,
Scheffe’s F test, Bonferroni/Dunn test, Kaplan-Meier
test, Logrank (Mantel-Cox) test and Student’s t test. A
p-value less than 0.05 were considered to be significant.
Results
Immunohistochemistry of 17βHSD1 and 17βHSD2
in NSCLC patients
Clinicopathological characteristics of the 103 NSCLC
patients examined were summarized in Tables 1 and 2.
17βHSD1 and 17βHSD2 immunoreactivity was detected
in the cytoplasm of 85% and 95% of the patients, re-
spectively (Table 1, Figure 1). A high 17βHSD1 immuno-
reactivity tended to be positively associated with tumor
stage (p=0.055) and aromatase (p=0.057), (Table 2). A
high 17βHSD2 immunoreactivity status was positively
associated with squamous cell and adenosquamous cell
carcinomas subtypes (p=0.031), tumor stage (p=0.004), T
factor of TNM classification (p=0.010), maximum tumor
diameter (p=0.002) and tended to be associated with N
factor of TMN classification (p=0.065) (Table 2). In
addition, among 17βHSD1 and 17βHSD2 double positive
patients (85 cases), a high status of 17βHSD1 was signifi-
cantly associated with that of 17βHSD2 (p=0.014).
Association of 17βHSD1 and 17βHSD2 with intratumoral
tissue Estrone and Estradiol concentrations in NSCLC
patients
The median with minimum-maximum value of tissue
concentration of E1 and E2 in lung cancer tissues was
170.5 pg/g (9.2-979.88) and 20.35 pg/g (4.2-233.88) in
this study. Thirty-four (71%) of 48 NSCLC cases demon-
strated higher E1 tissue concentration in carcinoma tis-
sues than the corresponding non-neoplastic lung tissues
from the same patients, and these intratumoral E1 con-
centrations tended to be higher than those detected in
their corresponding non-neoplastic lung tissues [148.6
(12.7-837.87) pg/g], (p=0.061), (Figure 2a). Tissue con-
centrations of E1 in men were significantly higher than
those detected in postmenopausal women both in
NSCLC (199.38 (104.43-979.88) pg/g in men and 141.11
(9.2-359.5) pg/g in postmenopausal women, p=0.006),
Table 1 Clinical and pathologic features of 103 NSCLC
patients
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(72.44-837.87) pg/g in men and 85.68 (12.7-281.2) pg/g
in postmenopausal women, p<0.0001). Tissue E1 con-
centrations were significantly lower in NSCLC with a
high 17βHSD1 status than that in patients with a low/
negative 17βHSD1 status (151.57 (9.2-367.25) pg/g in
high 17βHSD1 status and 197.08 (97.5-979.88) pg/g in
low/negative 17βHSD1 status, p=0.040) (Figure 2c).
Tissue E1 concentrations were, however, significantly
higher in NSCLC with a high 17βHSD2 status than that
in patients with a low or negative 17βHSD2 status
(194.28 (58.64-527.7) pg/g in high 17βHSD2 status and
163.89 (9.2-979.88) pg/g in low/negative 17βHSD2 sta-
tus, p=0.035) (Figure. 2(d)). There were no significant dif-
ferences in intratumoral E2 concentration according to
17βHSD1 status (p=0.613) and/or 17βHSD2 status
(p=0.177) (data not shown) but a higher intratumoral E2/
E1 ratio was significantly associated with a high 17βHSD1status than that in those with a low/negative 17βHSD1
status (p=0.028) (Figure 2e). No significant differences
were detected in intratumoral E2/ E1 ratio between a high
17βHSD2 status and that in patients with a low/negative
17βHSD1 status (p=0.404), (Figure 2f).
Association of 17βHSD1 and 17βHSD2 with clinical
outcome of NSCLC patients
17βHSD1 negative cases were significantly associated
with better overall survival when compared to 17βHSD1
positive ones (p=0.012), (Figure 2g). 17βHSD2 negative
cases were significantly associated with poorer overall
survival when compared to 17βHSD2 positive patients
(p=0.021), (Figure 2h) but cases with both higher
17βHSD1 and 17βHSD2 status when compared to those
with both low status were positively associated with
worse overall survival in NSCLC patient (p=0.012) and
(p=0.021) respectively (Figure 2g,h). A subsequent multi-
variate regression analysis, however, demonstrated that
only high 17βHSD1 status (HR= 2.83, p=0.007), sex
(HR= 2.22, p=0.039), tumor stage (HR= 3.97, p=0.041),
pT status (p=0.042), (HR= 2.83, p=0.007) and maximum
tumor diameter (HR=6.53, p=0.001) turned out inde-
pendent prognostic factors (Table 3).
Expression of 17βHSD1 and 17βHSD2 in NSCLC cell lines
We employed NSCLC cell lines A549 and LK87 express-
ing both aromatase and ERβ [23]. Quantitative RT-PCR
analysis demonstrated that both A549 and LK87 cells
express 17βHSD1 and 17βHSD2 mRNA (Figure 3a,b).
The amounts of 17βHSD1 mRNA expression was sig-
nificantly higher than that of 17βHSD2 in both of the
NSCLC cell lines examined (p<0.0001). However, the
amounts of 17βHSD2 mRNA expression was signifi-
cantly higher in NSCLC cells than in breast carcinoma
cells i.e. MCF-7, (p<0.0001).
Targeting 17βHSD1 activity in NSCLC cells
A 24-hour treatment with 100nM E1 resulted in a signifi-
cantly higher E2 production (5-fold) when compared to
treatment with 100 nM testosterone in both A549 and
LK87 cells (p=<0.0001), (Figure 3c). In addition, a 72 hour
treatment with aromatase inhibitor (letrozole) resulted in
up regulation of 17βHSD1 expression (Figure 3d). Two
17βHSD1 specific siRNA and a negative control of scram-
ble siRNA were selected and used according to a previous
report [22] in order to effectively knock down the expres-
sion of 17βHSD1 in these NSCLC cells. A 72 hour treat-
ment with 17βHSD1 siRNA 2 significantly lowered
endogenous 17βHSD1 expression in both A549 and LK87
cells (Figure 3e). In addition, a 72 hour E1 treatment in-
creased cell proliferation in both of the NSCLC cell lines
examined (p=<0.0001), which was also significantly
Table 2 Association between clinicopathological variables and 17βHSD1/ 17βHSD2 status in 103 NSCLC patients
103 cases 17βHSD1 17βHSD2
High n=51 Low/Negative n=52 P High n=54 Low/Negative n=49 P
SEX Male 31 31 36 26
Female 20 21 0.903 18 23 0.158
Histology Adeno 38 39 35 42
SCC 11 12 16 7
Adeno squamous 2 1 0.826 3 0 0.031
Stage I 28 40 27 41
II 7 2 7 2
III 15 8 18 5
IV 1 2 0.055 2 1 0.004
pT pT1 20 27 18 29
pT2 25 20 26 19
pT3 3 2 4 1
pT4 3 4 0.617 6 0 0.010
pN pN0 34 44 36 42
pN1 6 3 7 2
pN2 11 5 0.100 11 5 0.065
pM pM0 50 49 52 47
pM1 1 3 0.306 2 2 0.921
Diameter* 15-65 (30) 10-90 (27) 0.156 18-75 (31.5) 10-90 (24) 0.002
Ki-67 %* 0-54.2 (17.6) 0-47.2 (16.6) 0.697 0-54.2 (18.3) 0-47.2 (13.4) 0.127
ERα positive 15 9 0.244 14 10 0.641
negative 37 42 40 39
ERβ positive 49 43 0.097 50 42 0.257
negative 3 8 4 7
Aromatase positive 47 39 0.057 47 39 0.309
negative 5 12 7 10
Statistical analysis was conducted by Fisher exact test, Wilcoxon rank sum test, and Pearson χ2 test.
* Data were continuous variables and the median with minimum-maximum values were presented.
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(Figure 3f).
Discussion
In this study, we performed IHC analysis in 103 NSCLCs
for evaluating the expression of 17βHSD1 and 17βHSD2
enzymes in NSCLC tissues. Both 17βHSD1 and
17βHSD2 were immunolocalized in the cytoplasm of
carcinoma cells (Figure 1 Normal bronchial epithelial
cells detected in the specimens were only occasionally
weakly positive for either 17βHSD1 and/or 17βHSD2,
suggesting a possible up-regulation of these enzymes in
carcinoma cells. The majority of NSCLC cases examined
in this study were positive for either 17βHSD1 (85%)
and/or 17βHSD2 (95%) (Table 1). A relatively high num-
ber of NSCLC cases examined also demonstrated aro-
matase immunoreactivity (Table 1) as reported in manyprevious studies [7]. Intratumoral expression of estrogen
producing enzymes i.e. aromatase, 17βHSD1 and
17βHSD2, all indicated that biologically active estrogens
are actively synthesized either via aromatase and/or
17βHSDs pathway in NSCLC patients.
It is also true that 17βHSD1 and 17βHSD2 immunoreac-
tivity was very heterogeneous in NSCLC cases (Figure 1).
Therefore, based on relative immunointensity of either
17βHSD1 and/or 2 in cytoplasm of the tumor cells, the
cases were tentatively sub-classified as low (negative or
weakly positive) and high (moderately/strongly positive) as
previously reported in breast cancer [18]. In breast cancer
cases, the status of 17βHSD1 immunoreactivity in carcin-
oma cells was reported to be significantly correlated with
that of ER and PgR, suggesting that E2, synthesized by
17βHSD1 in carcinoma cells may act on these cells locally
[18]. However, in our present study of lung cancer, a
Figure 1 Representative illustrations of immunohistochemistry of 17βHSD1 and 17βHSD2 in cases of NSCLCs. Immunoreactivity was
detected in the cytoplasm with varying intensity patterns, i.e. no staining, low staining and high staining.
Verma et al. Journal of Translational Medicine 2013, 11:167 Page 6 of 11
http://www.translational-medicine.com/content/11/1/167relatively high immunoreactivity status of 17βHSD1 tended
to be positively associated with ERβ (p=0.097), aromatase
(p=0.057) and tumor stage (p=0.055) (Table 2), although
that of 17βHSD2 was not associated with either ERβ
(p=0.257) and/or aromatase status (p=0.309) (Table 2). In
addition, the status of ERα immunoreactivity was by no
means associated with either 17βHSD1 and/or 17βHSD2
statuses (Table 2), suggesting a more pronounced associ-
ation between ERβ and 17βHSD pathway. These findings
also suggest a potential interaction between intratumoral
aromatase and 17βHSD pathways signaling in lung carcin-
oma cells. However, a high 17βHSD2 status was signifi-
cantly associated with histological grade (p=0.031), tumor
stage (p=0.004), T factor of TMN classification (p=0.010),
maximum tumor diameter; (p=0.002) and also tended to
be associated with N factor of TMN classification
(p=0.065), (Table 2). These results indicated that 17βHSD2
may also play an important role in regulating lung cancer
biology.
It then becomes important to evaluate the contribu-
tion of 17βHSD pathway in NSCLC patient towards an
availability of intratumoral estrogens i.e. E2 and E1. In
this study, intratumoral E1 was significantly higher in
lung carcinoma tissue when compared to non-neoplastic
tissue of the same NSCLC patients (Figure 2a). In
addition, a high immmunointensity status of 17βHSD1
was associated with lower intratumoral E1 concentration
and that of 17βHSD2 with higher intratumral E1concentrations (Figure 2c,d). There were, however, no
significant differences in intratumoral E2 concentration
among patients having either high or low immmu-
nointensity status of 17βHSD1 or 2 (data not shown).
These results indicated that both 17βHSD1 and
17βHSD2 maintained a constant intratumoral E2 con-
centration equilibrium state by making use of available
E2 and E1 in situ. Therefore, it is important to analyze
whether these enzymes; i.e. 17βHSD1 and 17βHSD2,
contribute to the intratumoarl E2/E1 ratio in NSCLC
cells or not. A high E2/E1 ratio was reported to be posi-
tively correlated with the proliferation of estrogen
dependent breast carcinoma cells and its reduction is
also considered to be an effective mean of facilitating
breast cancer therapy [22]. In this study, a higher
intratumoral E2/E1 ratio was significantly associated
with a high immmunoreactivity status of 17βHSD1 than
that detected in patients with a low or negative
17βHSD1 status (p=0.028), (Figure 2e). These results
demonstrated that intratumoral 17βHSD1 is also im-
portant for determining the E2/E1 ratio in lung carcin-
oma cells as in breast cancer patients and targeting
17βHSD1 could possibly confer therapeutic benefits to
these estrogen dependent lung carcinoma patients.
In this study, among 17βHSD1 and 17βHSD2 double
positive cases (85 cases), both 17βHSD1 and 17βHSD2
were significantly correlated with each other (p=0.014). In
addition, the absence of 17βHSD1 in tumor cells was
Figure 2 Intratumoral estrogens concentration and overall survival in NSCLC patients. (a) Intratumoral concentration of estrone in 48
NSCLCs and corresponding non-neoplastic lung tissues. (b) Intratumoral concentration of E1 in male and female NSCLCs. Association between
intratumoral E1 concentration in 49 NSCLCs, (c) either with 17βHSD1 or (d) with 17βHSD2 enzymes. Association between intratumoral E2/E1
concentration in 49 NSCLCs, (e) either with 17βHSD1 or (f) with 17βHSD2 enzymes. The grouped data are represented as box plots. The median
value is shown by a horizontal line in the box plot and the box denotes the 75th (upper margin) and 25th percentiles of the values (lower
margin). Kaplan–Meier survival curves in 103 NSCLC patients, (g) according to 17βHSD1 immunoreactivity; negative vs. low vs. high and (h)
according to 17βHSD2 immunoreactivity; negative vs. low vs. high.
Verma et al. Journal of Translational Medicine 2013, 11:167 Page 7 of 11
http://www.translational-medicine.com/content/11/1/167
Table 3 Univariate and multivariate analyses for clinical outcome in 103 NSCLC patients
Variables Overall survival Hazard ratio
Univariate Multivariate (95% CI)
SEX 0.010* 0.039 2.22 (.90-5.49)
Histology 0.508 - -
Stage (I + II vs. III +IV) <0.0001* 0.041 3.97 (1.05-15.02)
pT <0.0001* 0.042 -
pN <0.0001* 0.054 -
pM 0.585 - -
Diameter (≥30 mm vs. <30mm) 0.002* 0.001 6.53 (2.14-19.86)
Ki-67 labeling (≥10% vs. < 10%) 0.010* 0.284 1.76 (0.62-4.98)
17βHSD1 (high vs. low/negative) 0.003* 0.007 2.83 (1.31-6.09)
17βHSD2 (high vs. low/negative) 0.023* 0.286 0.62 (0.26-1.48)
ERα expression 0.599 - -
ERβ expression 0.570 - -
Aromatase expression 0.639 - -
*Data were considered significant in the univariate analyses, and were examined in the multivariate analyses.
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(p=0.012) (Figure 2g) whereas the absence of 17βHSD2
with poorer overall survival of the patients examined
(p=0.021), (Figure 2h). A high immmunoereactivity status
of either 17βHSD1 (p=0.012) and/or 17βHSD2 (p=0.021)
was also significantly associated with poorer overall
survival when compared to lower statuses (Figure 2g,h).
E2 is well-known to stimulate breast and endometrial
carcinoma development. However, high doses of E2 are
also well known to induce regression of hormone-
dependent breast cancer in postmenopausal women
and cause apoptosis of carcinoma cells [23]. Therefore,
17βHSD2 in NSCLC patients may play a role in protecting
lung carcinoma cells from excessive stimulation of E2 by
inactivation of potent E2 to inactive E1 and maintaining
equilibrium status of constant E2 supply. Therefore, both
17βHSD1 and 17βHSD2 may work in tandem in order
to maintain an equilibrium state of constant E2 supply
in NSCLC tumor microenvironment. A multivariate
regression analyses further demonstrated that only
high 17βHSD1 status (HR= 2.83, p=0.007) and not high
17βHSD2 (p=0.286) status was an independent prognostic
factor (Table 3). These data clearly demonstrated the
prognostic significance of 17βHSD pathways in estrogen
dependent NSCLC patients. In addition, in this study
clinical impact of 17βHSD1 was much higher than that
of ERβ (Table 3) suggesting that E2 may also have some
other important functions besides ERβ mediated actions
in NSCLCs, as suggested by earlier studies in breast
cancer [24]. However, further investigations are definitely
required for better clarifications.
Earlier studies demonstrated both A549 and LK87
cells as estrogen dependent NSCLC cell lines expressingaromatase [25,26]. Both of these cell lines expressed
higher 17βHSD1 mRNA level when compared to
17βHSD2 suggesting a more pronounced role of
17βHSD1 in these NSCLC cells (Figure 3a,b). This
17βHSD1 activity resulted in significantly higher E2 pro-
duction (5-fold) when compared to aromatase activity in
both A549 and LK87 cells (p<0.0001) (Figure 3c). This
difference could be due to a higher 17βHSD1 level when
compared to aromatase in these NSCLC cell lines [25].
We observed an increment of both 17βHSD1 following
AI therapy in these NSCLC cell lines suggesting a pos-
sible emergence of 17βHSD pathway, (Figure 3d). This
increment may represent a possible adaptation of carcin-
oma cells in response to intratumoral estrogen depletion,
in lung cancer cells. We have recently demonstrated a
similar increment of 17βHSD1 following aromatase in-
hibitor (exemestane) treatment in the group associated
with decreased Ki67 labeling index or clinical responders
in breast cancer patients [27]. This result also suggests
that 17βHSD enzymes may represent as a potent marker
for response to aromatase inhibitor therapy in the lung
carcinoma, but it awaits further examinations. Finally, E1
treatment stimulated cell proliferation in both cell lines
above which was significantly inhibited by 17βHSD1
siRNA 2 transfection, (p<0.0001) (Figure 3f).
Conclusion
These results all suggested that in addition to intratumoral
production via aromatase pathway, 17βHSD1 is active and
contributes to tumor progression of estrogen dependent
NSCLC cells by making use of available intratumoral E1.
Therefore, potential endocrine therapy targeting 17βHSD1
may translate into therapeutic benefits to estrogen
Figure 3 17βHSD1 expression and activity in NSCLC cell lines. (a) mRNA expression of 17βHSD1 and (b) 17βHSD2 enzymes. Positive control,
MCF-7 cells. (c) E2 production via intratumoral 17βHSD1 activity and intratumoral aromatase activity on 24hrs of treatment with either E1 or
testosterone, respectively. (d) Expression of 17βHSD1 following aromatase inhibitor treatment. (e) 17βHSD1 siRNA assisted 17βHSD1 knockdown
after 72hrs of siRNA treatment. siRNA-C: scramble siRNA; siRNA1: 17βHSD1 specific siRNA1 and siRNA2: 17βHSD1 specific siRNA2. (f) Proliferation
after 72hrs of treatment with either with E1 and/or 17βHSD1 specific siRNA. Data represent 3 independent experiments, each performed in
triplicate. Results are represented as mean ± SD. All immunoblots are representative of 3 independent experiments.
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http://www.translational-medicine.com/content/11/1/167dependent NSCLC patients. Therefore, similar to estrogen
dependent breast cancer patients, 17βHSD1 inhibitors ei-
ther alone or in combination with aromatase inhibitors
may represent a novel approach for treating estrogendependent lung cancer patients. It is also important to
note that, in addition to 17βHSD1 and 17βHSD2, other
sub-types of 17βHSDs were also reported to be implicated
in various hormone dependent carcinomas [28]. These
Verma et al. Journal of Translational Medicine 2013, 11:167 Page 10 of 11
http://www.translational-medicine.com/content/11/1/16717βHSD subtypes may therefore, be reasonably be postu-
lated to play important roles in hormone dependent hu-
man lung cancer patients. However, further investigations
are definitely required for clarifications.
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